Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

I-Mab Plans to Partner its CD-47 Immunotherapy in $2 Billion Deal

publication date: Apr 29, 2020

According to Bloomberg, I-Mab BioPharma of Shanghai is shopping its CD-47 immunoncology candidate to various global biopharmas with hopes of forming a $2 billion collaboration. I-Mab believes TJC4 is a potential global best-in-class CD47 because it binds to a unique epitope on CD47 that leads to only minimal red blood cell binding. In pre-clinical studies, it did not cause anemia, thrombocytopenia or the so-called "antigen sink effect." Like other CD47 candidates, TJC4 works by preventing microphages from being neutralized by the patient's immune system. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here